Terlipressin + Albumin Versus Midodrine + Octreotide in the Treatment of Hepatorenal Syndrome

Stopped Decision of independent monitoring committee: Risk of non-response to treatment significantly higher in midodrine group than in terlipressin group.

Conditions

• Cirrhosis
• Hepatorenal Syndrome

Interventions

• DRUG: Terlipressin plus albumin
• DRUG: Midodrine plus octreotide plus human albumin

Sponsor

University of Padova